Mammoth Biosciences is a biotechnology company utilizing proprietary ultracompact CRISPR systems to develop long-term curative therapies and innovative precision diagnostics. Founded by Nobel laureate Jennifer Doudna and her expert team, Mammoth is focused on enabling in vivo gene editing across challenging tissues, employing cutting-edge techniques such as base editing, epigenetic editing, and gene writing. The company is actively expanding its pipeline of in vivo gene editing therapeutics and collaborates with prominent pharmaceutical and biotech partners to extend the application of its technology. With a strong foundation in scientific research and a commitment to advancing the potential of CRISPR technologies, Mammoth aims to transform patient outcomes through novel therapeutic interventions. The company fosters an inclusive workplace culture and encourages diverse perspectives to empower its teams in driving impactful scientific solutions.